Merrimack Pharmaceuticals, Inc. (MACK) News
Filter MACK News Items
MACK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MACK News From Around the Web
Below are the latest news stories about MERRIMACK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MACK as an investment opportunity.
Merrimack Reports Third Quarter 2023 Financial ResultsCAMBRIDGE, Mass., November 02, 2023--Merrimack Reports Third Quarter 2023 Financial Results |
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) most popular amongst retail investors who own 39% of the shares, institutions hold 33%Key Insights Significant control over Merrimack Pharmaceuticals by retail investors implies that the general public has... |
Merrimack Reports Second Quarter 2023 Financial ResultsCAMBRIDGE, Mass., August 03, 2023--Merrimack Reports Second Quarter 2023 Financial Results |
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, Merrimack... |
Merrimack Reports First Quarter 2023 Financial ResultsCAMBRIDGE, Mass., May 04, 2023--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [("Merrimack" or the "Company")] today announced its first quarter 2023 financial results for the period ended March 31, 2023. |
Retail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds account for 33%Key Insights Significant control over Merrimack Pharmaceuticals by retail investors implies that the general public has... |
Merrimack Reports Full Year 2022 Financial ResultsCAMBRIDGE, Mass., March 09, 2023--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2022 financial results for the period ended December 31, 2022. |
Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its BusinessWe can readily understand why investors are attracted to unprofitable companies. For example, Merrimack Pharmaceuticals... |
12 Best Performing Biotech Stocks in 2022In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […] |
Bullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last yearUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |